Rhovac board member resigns due to health reasons
LUND, Sweden, Oct. 18, 2022 /PRNewswire/ -- RhoVac AB (publ) announces today, October 18th 2022, that board member and co-founder Anders Ljungqvist is resigning from the board at his own request due to health reasons. Gunnar Gårdemyr, chairman of the board, comments: "On behalf of the board, I w...
Pre-clinical findings support the potential use of RhoVac's drug candidate, onilcamotide, across several cancers
STOCKHOLM, May 19, 2022 /PRNewswire/ -- RhoVac AB ("RHOVAC") today, 18th May 2022, announces preclinical findings from its collaboration with St. John's Research Institute (SJRI), a unit of CBCI Society for Medical Education, in Bangalore India. These findings support the hypothesised tissue agnos...
RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide
STOCKHOLM, Sweden, May 11, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company,announced on May 10th, 2022, that its phase IIb study in prostate cancer, BRaVac, has reached "Database Lock". This means that all data from the trial is now finally reported, cleaned and...
RhoVac retains international investment bank as advisor for desired RV001 transaction
STOCKHOLM, Oct. 11, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,October 11, 2021, that it has retained the services of Stifel Nicolaus Europe Limited ("Stifel"), a global investment bank, as its exclusive financial adviser in connection with ...
RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer
STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onOctober 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 20...
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer
STOCKHOLM, April 21, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,April 21st 2021, that the prestigiousMount Sinai hospital in New York is initiated today as the latest addition to US trial centres in RhoVac's clinical phase IIb study, "BRaVac...
Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study
STOCKHOLM, March 9, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,March 8th , 2021, that its clinical phase IIb study, "BRaVac", in prostate cancer, will be somewhat further delayed as Covid-19 vaccinations are rolled out to the study populatio...
First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom
STOCKHOLM, Jan. 7, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in United Kingdom is enroll...
Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer
STOCKHOLM, Nov. 13, 2020 /PRNewswire/ -- RhoVac announces today, November 13, 2020, that the results of its clinical phase I/II study have been published in the Journal for ImmunoTherapy of Cancer (JITC). The scientifically reviewed article reports that the treatment with RhoVac's drug candidate ...
First patient in treatment in RhoVac's clinical phase IIb study in Sweden
STOCKHOLM, Sept. 17, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, onSeptember 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in Sweden is enrolled in the cli...
RhoVac appoints Professor Georg Hollaender to its Scientific Advisory Board
STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today September 4th 2020, that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing ProfessorGeorg Hollaender, Action Research Professor and Head of Department at Oxford ...
First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany
STOCKHOLM, April 24, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on 23rd April 2020, that the first patient in Germany is in treatment in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac"). The first patient in Germany is in treatment...
